Switching Medications: Sandostatin to Lanreotide

This chapter addresses a listener's concerns about transitioning from sandostatin LAR to lanreotide, emphasizing medication efficacy and dosages. It also explores patient experiences, potential side effects, and the latest clinical trials in neuroendocrine tumor treatments.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app